Abstract
Mucormycosis has emerged as an important fungal infection with high morbidity and mortality. The genera Rhizopus, Lichtheimia, and Mucor are most often recovered from clinical specimens and are ubiquitous in nature, but their precise ecology remains to be determined. Cases with mucormycosis have been reported from all over the world, and seasonal variation is possible. Israel reported that 16 of 19 rhino-orbitocerebral mucormycosis cases occurred in autumn [1], and in Japan, 6 of 7 pulmonary mucormycosis cases developed from August to September [2]. However, others report invasive cases all of the year [3–7]. There are several factors that limit our ability to accurately determine the exact incidence of mucormycosis. First, these infections are not reportable; the risk varies widely in different populations, and the proof of diagnosis is extremely difficult to obtain. Mucormycosis remains an uncommon disease, even in high-risk patients, and represents between 4 and 23% of all fungal infections in patients at risk [3–5]. Postmortem evaluation showed mucormycosis being 10–50-fold less frequent than candidiasis or aspergillosis with a frequency of 1–5 cases per 10,000 autopsies [3–7]. The epidemiology of mucormycosis varies between developed and developing countries. In developed countries the disease is most often seen in patients with hematological malignancies undergoing chemotherapy or who received allogeneic stem cell transplants (HSCT) [8]. Roden et al. compiled 929 cases of mucormycosis and displayed an increasing proportion of immunocompromised patients with mucormycosis in the 1980s and 1990s [9]. The registry of the European Confederation of Medical Mycology Working Group recorded 230 cases between 2005 and 2007 and found patients with hematological malignancies (44%), trauma (15%), HSCT (9%), and diabetes mellitus (9%) being infected [10]. Similar data were obtained by a French analysis comprising 101 cases of mucormycoses (60 proven and 41 probable cases), mostly in men (58%) older than >50 years (mean age, 50.7 ± 19.9 years). The incidence increased from 0.7 cases per 1 million in 1997 to 1.2 cases per 1 million in 2006 (P < 0.001) [11]. An active population-based surveillance study from California calculated an annual incidence of mucormycosis of 1.7 cases per 1 million individuals (∼500 cases per year) [12]. An incidence of 0.43 cases per 1 million inhabitants or 0.62 cases per 100,000 hospital admissions was rated for Spain [13]. In developing countries, especially in India, mucormycosis occurs mainly in patients with uncontrolled diabetes or trauma [14, 15].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Talmi YP, Goldschmied-Reouven A, Bakon M et al (2002) Rhino-orbital and rhino-orbitocerebral mucormycosis. Otolaryngol Head Neck Surg 127:22–31
Funada H, Matsuda T (1996) Pulmonary mucormycosis in a hematology ward. Intern Med 35:540–544
Kume H, Yamazaki T, Abe M et al (2003) Increase in aspergillosis and severe mycotic infection in patients with leukemia and MDS: comparison of the data from the Annual of the Pathological Autopsy Cases in Japan in 1989, 1993 and 1997. Path Intern 53:744–750
Chamilos G, Luna M, Lewis RE et al (2006) Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 91:986–989
Hotchi M, Okada M, Nasu T (1980) Present state of fungal infections in autopsy cases in Japan. Am J Clin Pathol 74:410–416
Tietz HJ, Brehmer D, Janisch W, Martin H (1998) Incidence of endomycoses in the autopsy material of the Berlin Charité Hospital. Mycoses 41:81–85
Yamazaki T, Kume H, Murase S et al (1999) Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 37:1732–1738
Spellberg B, Edwards J Jr, Ibrahim A (2005) Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18:556–569
Roden MM, Zaoutis TE, Buchanan WL et al (2005) Epidemiology and outcome of mucormycosis: a review of 929 reported cases. Clin Infect Dis 41:634–653
Skiada A, Pagano L, Groll A et al (2007) Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 17:1859–1867
Bitar D, Van Cauteren D, Lanternier F et al (2009) Increasing incidence of zygomycosis (mucormycosis), France 1997-2006. Emerg Infect Dis 15:1395–1401
Rees JR, Pinner RW, Hajjeh RA et al (1998) The epidemiological features of invasive mycotic infections in the San Francisco Bay area 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 27:1138–1147
Torres Narbona M, Guinea J, Martinez-Alarcon J et al (2007) Impact of mucormycosis on microbiology overload: a survey study in Spain. J Clin Microbiol 45:2051–2053
Prabhu RM, Patel R (2004) Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 10:31–47
Chakrabarti A, Das A, Mandal J et al (2006) The rising trend of invasive mucormycosis in patients with uncontrolled diabetes mellitus. Med Mycol 44:335–342
Buzina W, Braun H, Freudenschuss K et al (2003) Fungal biodiversity – as found in nasal mucus. Med Mycol 41:149–161
Ribes JA, Vanover-Sams CL, Baker DJ (2000) Zygomycetes in human diseases. Clin Microbiol Rev 13:236–301
Petrikkos GL, Skiada A, Sambatakou H et al (2003) Mucormycosis: ten year experience in a tertiary-care centre in Greece. Eur J Clin Microbiol Infect Dis 22:753–756
Antoniadou A (2009) Outbreaks of mucormycosis in hospitals. Clin Microbiol Infect 15:55–59
Cheng VC, Chan JF, Ngan AH et al (2009) Outbreak of intestinal infection due to Rhizopus microsporus. J Clin Microbiol 47:2834–2843
Gonzalez CE, Rinaldi MG, Sugar AM (2002) Mucormycosis. Infect Dis Clin N Am 16:895–914
Rogers TR (2008) Treatment of mucormycosis: current and new options. J Antimicrob Chemother 61:35–39
Goodman NL, Rinaldi MG (1991) Agents of mucormycosis. In: Balows A, Hausler WJ, Herrmann KL, Isenberg HD, Shadoomy HJ (eds) Manual of clinical microbiology, 5th edn. ASM Press, Washington, pp 674–692
Lopes JO, Pereira DV, Streher LA et al (1995) Cutaneous mucormycosis caused by Absidia corymbifera in a leukemic patient. Mycopathologia 130:89–92
Stas KJF, Louwagie GLH, Van Damme BJC et al (1996) Isolated mucormycosis in a bought living unrelated kidney transplant. Transpl Int 9:600–602
Zaoutis TE, Roilides E, Chiou CC et al (2007) Mucormycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J 26:723–727
Tedder M, Spratt JA, Anstadt MP et al (1994) Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 57:1044–1050
Gupta KL, Khullar DK, Behera D et al (1998) Pulmonary mucormycosis presenting as fatal massive haemoptysis in a renal transplant recipient. Nephrol Dial Transplant 13:3258–3260
Kitabayashi A, Hirokawa M, Yamaguchi A, Takatsu H, Miura AB (1998) Invasive pulmonary mucormycosis with rupture of the thoracic aorta. Am J Hematol 58:326–329
Passamonte PM, Dix JD (1985) Nosocomial pulmonary mucormycosis with fatal massive hemoptysis. Am J Med Sci 289:65–68
Connor BA, Anderson RJ, Smith JW (1979) Mucor mediastinitis. Chest 75:525–526
Hsu JW, Chiang CD (1996) A case report of novel roentgenographic finding in pulmonary mucormycosis: thickening of the posterior tracheal band. Kaohsiung J Med Sci 12:595–600
Rubin SA, Chaljub G, Winer-Muram HT, Flicker S (1992) Pulmonary mucormycosis: a radiographic and clinical spectrum. J Thorac Imaging 7:85–90
McAdams HP, Rosado de Christenson M, Strollo DC, Path EF Jr (1997) Pulmonary mucormycosis: radiologic findings in 32 cases. Am J Roentgenol 168:1541–1548
Dykhuizen RS, Kerr KN, Soutar RL (1994) Air crescent sign and fatal haemoptysis in pulmonary mucormycosis. Scand J Infect Dis 26:498–501
Funada H, Misawa T, Nakao S et al (1984) The air crescent sign of invasive pulmonary mucormycosis in acute leukemia. Cancer 53:2721–2723
Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP (2005) Predictors of pulmonary mucormycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41:60–66
Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM (2008) Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis 46:1733–1737
Meyer RD, Rosen P, Armstrong D (1972) Phycomycosis complicating leukemia and lymphoma. Ann Intern Med 77:871–879
Hosseini SM, Borghei P (2005) Rhinocerebral mucormycosis: pathways of spread. Eur Arch Otorhinolaryngol 262:932–938
Orguc S, Yuceturk AV, Demir MA, Goktan C (2005) Rhinocerebral mucormycosis: perineural spread via the trigeminal nerve. J Clin Neurosci 12:484–486
Franquet T, Gimenez A, Hidalgo A (2004) Imaging of opportunistic fungal infections in immunocompromised patient. Eur J Radiol 51:130–138
Garces P, Mueller D, Trevenen C (1994) Rhinocerebral mucormycosis in a child with leukemia: CT and MR findings. Pediatr Radiol 24:50–51
Oliveira-Neto MP, Da Silva M, Monteiro PCF et al (2006) Cutaneous mucormycosis in a young, immunocompetent girl. Med Mycol 44:567–570
Hampson FG, Ridgway EJ, Feeley K, Reilly JT (2005) A fatal case of disseminated mucormycosis associated with the use of blood glucose self-monitoring equipment. J Infect 51:e269–e272
Hocker TL, Wada DA, Bridges A, El-Azhary R (2010) Disseminated mucormycosis heralded by a subtle cutaneous finding. Dermatol Online J 16:3
Rubin AI, Grossman ME (2004) Bull’s-eye cutaneous infarct of mucormycosis: a bedside diagnosis confirmed by touch preparation. J Am Acad Dermatol 51:996–1001
Kerr OA, Bong C, Wallis C, Tidman MJ (2004) Primary cutaneous mucormycosis masquerading as pyoderma gangrenosum. Br J Dermatol 150:1212–1234
Diven SC, Angel CA, Hawkins HK, Rowen JL, Shattuck KE (2004) Intestinal mucormycosis due to Absidia corymbifera mimicking necrotizing enterocolitis in a preterm neonate. J Perinatol 24:794–796
Mitchell SD, Gray J, Morgan ME et al (1996) Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. Lancet 348:441–443
Michalak DM, Cooney DR, Rhodes KH, Telander RL, Kleinberg F (1980) Gastrointestinal mucormycoses in infants and children: a cause of gangrenous intestinal cellulitis and perforation. J Pediatr Surg 15:320–324
Garg PK, Gupta N, Gautam V, Hadke NS (2008) Gastric mucormycosis: unusual cause of gastric perforation in an immunocompetent patient. South Med J 101:449–450
Bittencourt AL, Ayala MA, Ramos EA (1979) A new form of abdominal mucormycosis different from mucormycosis: report of two cases and review of the literature. Am J Trop Med Hyg 28:564–569
Oliver MR, Van Voorhis WC, Boeckh M et al (1996) Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 22:521–524
Ismail MH, Hodkinson HJ, Setzen G, Sofianos C, Hale MJ (1990) Gastric mucormycosis. Trop Gastroenterol 11:103–105
Geramizadeh B, Modjalal M, Nabai S et al (2007) Gastrointestinal mucormycosis: a report of three cases. Mycopathologia 164:35–38
Echo A, Hovsepian RV, Shen GK (2005) Localized cecal mucormycosis following renal transplantation. Transpl Infect Dis 7:68–70
Virk SS, Singh RP, Arora AS, Grewal JS, Puri H (2004) Gastric mucormycosis – an unusual cause of massive upper gastrointestinal bleed. Indian J Gastroenterol 23:146–147
Azadeh B, McCarthy DO, Dalton A, Campbell F (2004) Gastrointestinal mucormycosis: two case reports. Histopathology 44:298–300
Park YS, Lee JD, Kim TH et al (2002) Gastric mucormycosis. Gastrointest Endosc 56:904–905
Siu KL, Lee WH (2004) A rare cause of intestinal perforation in an extreme low birth weight infant – gastrointestinal mucormycosis: a case report. J Perinatol 24:319–321
Cherney CL, Chutuape A, Fikrig MK (1999) Fatal invasive gastric mucormycosis occurring with emphysematous gastritis: case report and literature review. Am J Gastroenterol 94:252–256
Liu MF, Chen FF, Hsiue TR, Liu CC (2000) Disseminated mucormycosis simulating cerebrovascular disease and pulmonary alveolar haemorrhage in a patient with systemic lupus erythematosus. Clin Rheumatol 19:311–314
Tomita T, Ho H, Allen M, Diaz J (2005) Mucormycosis involving lungs, heart and brain, superimposed on pulmonary edema. Pathol Int 55:202–205
Fujii T, Takata N, Katsutani S, Kimura A (2003) Disseminated mucormycosis in an acquired immunodeficiency syndrome (AIDS) patient. Intern Med 42:129–130
Richardson MD, Warnock DW (2003) Mucormycosis. In: Richardson MD, Warnock DW (eds) Fungal infection diagnosis and management. Blackwell, Oxford, pp 230–240
Ingram CW, Sennesh J, Cooper JN, Perfect JR (1989) Disseminated mucormycosis: report of four cases and review. Rev Infect Dis 11:741–754
Virmani R, Connor DH, McAllister HA (1982) Cardiac mucormycosis: a report of five patients and review of 14 previously reported cases. Am J Clin Pathol 78:42–47
McNab AA, McKelvie P (1997) Iron overload is a risk factor for mucormycosis. Arch Ophthalmol 115:919–921
Sanchez-Recalde A, Merino JL, Dominguez F et al (1999) Successful treatment of prosthetic aortic valve mucormycosis. Chest 116:1818–1820
Levy E, Bia MJ (1995) Isolated renal mucormycosis: case report and review. J Am Soc Nephrol 5:2014–2019
Nagy-Agren SE, Chu P, Smith GJ et al (1995) Zygomycosis (mucormycosis) and HIV infection: report of three cases and review. J Acquir Immune Defic Syndr Hum Retrovirol 10:441–449
Weng DE, Wilson WH, Little R, Walsh TJ (1998) Successful medical management of isolated renal zygomycosis: case report and review. Clin Infect Dis 26:601–605
Langston C, Roberts DA, Porter GA, Bennett WM (1973) Renal phycomycosis. J Urol 109:941–944
Melnick JZ, Latimer J, Lee EI, Heinrich WL (1995) Systemic mucormycosis complicating acute renal failure: case report and review of the literature. Ren Fail 17:619–627
Chkhotua A, Yussim A, Tovar A et al (2001) Mucormycosis of the renal allograft: case report and review of the literature. Transpl Int 14:438–441
Weng DE, Wilson WH, Little R, Walsh TJ (1998) Successful medical management of isolated renal mucormycosis: case report and review. Clin Infect Dis 26:601–605
Mishra B, Mandal A, Kumar N (1992) Mycotic prosthetic-valve endocarditis. J Hosp Infect 20:122–125
Solano T, Atkins B, Tambosis E, Mann S, Gottlieb T (2000) Disseminated mucormycosis due to Saksenaea vasiformis in an immunocompetent adult. Clin Infect Dis 30:942–943
Zhang R, Zhang JW, Szerlip HM (2002) Endocarditis and hemorrhagic stroke caused by Cunninghamella bertholletiae infection after kidney transplantation. Am J Kidney Dis 40:842–846
Kalayjian RC, Herzig RH, Cohen AM, Hutton MC (1988) Thrombosis of the aorta caused by mucormycosis. South Med J 81:1180–1182
Mehta NN, Romanelli J, Sutton MG (2004) Native aortic valve vegetative endocarditis with Cunninghamella. Eur J Echocardiogr 5:156–158
Gubarev N, Separovic J, Gasparovic V, Jelic I (2007) Successful treatment of mucormycosis endocarditis complicated by pulmonary involvement. Thorac Cardiovasc Surg 55:257–258
Burke WV, Zych GA (2002) Fungal infection following replacement of the anterior cruciate ligament: a case report. J Bone Joint Surg 84A:449–453
Pierce PP, Wood MB, Roberts GD et al (1987) Saksenaea vasiformis osteomyelitis. J Clin Microbiol 25:933–935
Holtom PD, Obuch AB, Ahlmann ER, Shepherd LE, Patzakis MJ (2000) Mucormycosis of the tibia: a case report and review of the literature. Clin Orthop 381:222–228
Ben-Ami R, Luna M, Lewis RE, Walsh TJ, DP Kontoyiannis DP (2009) A clinicopathological study of pulmonary mucormycosis in cancer patients: extensive angioinvasion but limited inflammatory response. J Infect 59:134–138
Cornely OA, Arikan-Akdagli S, Dannaoui E et al (2014) ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect 20:5–26
Ribes JA, Vanover-Sams CL, Baker DJ (2000) Zygomycetes in human disease. Clin Microbiol Rev 13:236–301
Lass-Flörl C (2009) Zygomycosis: conventional laboratory diagnosis. Clin Microbiol Infect 5:60–65
Lass-Flörl C, Resch G, Nachbaur D et al (2007) The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis 45:e101–e104
Kontoyiannis DP, Chamilos G, Hassan SA et al (2007) Increased culture recovery of zygomycetes under physiologic temperature conditions. Am J Clin Pathol 127:208–212
Padhye AA, Ajello L (1988) Simple method of inducing sporulation by Apophysomyces elegans and Saksenaea vasiformis. J Clin Microbiol 26:1861–1863
Kontoyiannis DP, Lionakis MS, Lewis RE et al (2005) Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case–control observational study of 27 recent cases. J Infect Dis 191:1350–1360
Dolatabadi S, Kolecka A, Versteeg M, de Hoog SG, Boekhout T (2015) Differentiation of clinically relevant Mucorales Rhizopus microsporus and R. arrhizus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS). J Med Microbiol 64:694–701
Caramalho R, Maurer E, Binder U et al (2015) Etest cannot be recommended for in vitro susceptibility testing of Mucorales. Antimicrob Agents Chemother 59:3663–3665
Hsiao CR, Huang L, Bouchara J-P et al (2005) Identification of medically important molds by an oligonucleotide array. J Clin Microbiol 43:3760–3768
Nagao K, Ota T, Tanikawa A et al (2005) Genetic identification and detection of human pathogenic Rhizopus species, a major mucormycosis agent, by multiplex PCR based on internal transcribed spacer region of rRNA gene. J Dermatol Sci 39:23–31
Larché J, Machouart M, Burton K et al (2005) Diagnosis of cutaneous mucormycosis due to Rhizopus microsporus by an innovative PCR-restriction fragment-length polymorphism method. Clin Infect Dis 41:1362–1365
Machouart M, Larché J, Burton K et al (2006) Genetic identification of the main opportunistic mucorales by PCR-restriction fragment length polymorphism. J Clin Microbiol 44:805–810
Nyilasi I, Papp T, Csernetics Á et al (2008) High-affinity iron permease (FTR1) gene sequence-based molecular identification of clinically important Zygomycetes. Clin Microbiol Infect 14:393–397
Kasai M, Harrington SM, Francesconi A et al (2008) Detection of a molecular biomarker for zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol 46:3690–3702
Spellberg B, Walsh TJ, Kontoyiannis DP et al (2009) Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis 48:1743–1751
Farmakiotis D, Kontoyiannis DP (2016) Mucormycoses. Infect Dis Clin N Am 30:143–163
McCarthy M, Rosengart A, Schuetz AN et al (2014) Mold infections of the central nervous system. N Engl J Med 371:150–160
Brown RB, Johnson JH, Kessinger JM, Sealy WC (1992) Bronchovascular mucormycosis in the diabetic: an urgent surgical problem. Ann Thorac Surg 53:854–855
Gonzalez CE, Couriel DR, Walsh TJ (1997) Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor. Clin Infect Dis 24:192–196
Spanakis EK, Aperis G, Mylonakis E (2006) New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin Infect Dis 43:1060–1068
Sun QN, Fothergill AW, McCarthy DI et al (2002) In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 46:1581–1582
Thompson GR, Wiederhold NP (2010) Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 170:291–313
Arendrup MC, Jensen RH, Meletiadis J (2015) In vitro activity of isavuconazole and comparators against clinical isolates of the mucorales order. Antimicrob Agents Chemother 59:7735–7742
Noxafil (posaconazole). Highlights of prescribing information. https://www.merck.com/product/usa/pi_circulars/n/noxafil/noxafil_pi.pdf. Accessed 18 March 2014
Marti FM, Ostrosky-Zeichner L, Cornely OA et al (2016) Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis 16:828–837
Cresemba (isavuconazonium sulfate). Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207500Orig1s000lbl.pdf. Accessed 9 March 2015
Kontoyiannis DP, Lewis RE (2011) How I treat mucormycosis. Blood 118:1216–1224
Yohai RA, Bullock JD, Aziz AA, Markert RJ (1994) Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 39:3–22
Ferguson BJ, Mitchell TG, Moon R et al (1988) Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 10:551–559
Bentur Y, Shupak A, Ramon Y et al (1998) Hyperbaric oxygen therapy for cutaneous/soft-tissue zygomycosis complicating diabetes mellitus. Plast Reconstr Surg 102:822–824
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Maria, A., Cornelia, LF. (2019). Clinical Syndromes: Mucormycosis. In: Presterl, E. (eds) Clinically Relevant Mycoses. Springer, Cham. https://doi.org/10.1007/978-3-319-92300-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-92300-0_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-92299-7
Online ISBN: 978-3-319-92300-0
eBook Packages: MedicineMedicine (R0)